ORIC Stock: Price, Earnings History and SEC Filings
ORIC Pharmaceuticals, Inc. (ORIC) last traded at $9.24, up 2.78% on the latest session and down 31.4% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.38 against an analyst estimate of $-0.36, a miss of 5.6%.
$9.24 +2.78%
1 month-31.40%
52-week high$14.68
52-week low$7.23
Volume2.44M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ORIC earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 3, 2026 | $-0.38 | $-0.36 | -5.56% |
| Mar 2026 | May 4, 2026 | $-0.34 | $-0.31 | -9.68% |
| Dec 2025 | Feb 23, 2026 | $-0.30 | $-0.34 | +11.76% |
| Sep 2025 | Nov 13, 2025 | $-0.33 | $-0.41 | +19.51% |
ORIC beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for ORIC
SEC filing data is not available right now. You can search for ORIC on SEC EDGAR.
ORIC news
- ORIC Pharmaceuticals (ORIC) Stock Sees Modest Fair Value Lift On Trial Catalyst OptimismOct 27, 2026 · finance.yahoo.com
- ORIC Pharmaceuticals Sinks 22% as J&J Presents Rival Prostate Cancer DataOct 26, 2026 · tikr.com
- Oric Pharmaceuticals’ Enozertinib Shows 88% Response Rate in EGFR Lung Cancer StudyOct 23, 2026 · marketbeat.com
- ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026Oct 23, 2026 · finance.yahoo.com
- ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 TrialOct 23, 2026 · finance.yahoo.com
- ORIC Stock In Focus As New Lung Cancer Trial Data Heads To ESMO 2026Oct 21, 2026 · finance.yahoo.com
- Why ORIC Pharmaceuticals, Inc.’s (ORIC) Stock Is Up 10.06%Oct 19, 2026 · aaii.com
- ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026Oct 19, 2026 · finance.yahoo.com
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc. (ORIC) is a US-listed public company on Nasdaq.